Allogene Therapeutics ALLO
NASDAQ ALLO
$1.54 -0.06 (-3.75%)
At close: Oct 1, 2026 · 4:00 PM EDT

Allogene Therapeutics (ALLO) Cash from Financing Activities (2018 - 2026)

Updated

Allogene Therapeutics (ALLO) recorded Cash from Financing Activities of $187.87 million in Q2 2026, compared with $5.07 million a year earlier and up 789.5% from the prior quarter.

Analysis

Allogene Therapeutics (ALLO) Cash from Financing Activities (2018 - 2026) Analysis & Trends

On a TTM basis, Allogene Therapeutics' Cash from Financing Activities came in at $220.09 million as of Jun 30, 2026, up 763.6% year-over-year; for FY2025, it came in at $30.16 million, down 74.2% from FY2024.

  • Annual Cash from Financing Activities has a five-year compound annual growth rate of -45.6% (FY2020 to FY2025).
  • Across earlier years, Cash from Financing Activities came in at $116.68 million in FY2024 (+21.9%), $95.7 million in FY2023, $2.95 million in FY2022 (-75.3%) and $11.96 million in FY2021 (-98.1%).
  • The Q2 2026 figure is the highest quarterly Cash from Financing Activities since Q2 2020.
  • On a year-over-year basis, Cash from Financing Activities rose in four of the last six quarters, with growth averaging 172.1%.
  • Peak year-over-year performance for Cash from Financing Activities in the last five years was growth of 747.9% in Q1 2025, against a decline of 99.3% in Q2 2022 at the low end.
  • Per Business Quant, the preceding three quarters came in at $21.12 million (Q1 2026), $7.86 million (Q4 2025) and $3.24 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -8.78 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -5.05 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 1.76 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -2.02 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -47.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -1.48 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 2.34 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -3.66 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -426.70 Mn
10 Allogene Therapeutics 552.55 Mn 552.55 Mn - 187.87 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 187.87 Mn
Mar 31, 2026 21.12 Mn
Dec 31, 2025 7.86 Mn
Sep 30, 2025 3.24 Mn
Jun 30, 2025 5.07 Mn
Mar 31, 2025 13.99 Mn
Dec 31, 2024 5.74 Mn
Sep 30, 2024 679,000.00
Jun 30, 2024 108.60 Mn
Mar 31, 2024 1.65 Mn
Dec 31, 2023 155,000.00
Sep 30, 2023 4.29 Mn
Jun 30, 2023 89.52 Mn
Mar 31, 2023 1.73 Mn
Dec 31, 2022 46,000.00
Sep 30, 2022 1.07 Mn
Jun 30, 2022 24,000.00
Mar 31, 2022 1.81 Mn
Dec 31, 2021 322,000.00
Sep 30, 2021 2.38 Mn
API Access

Allogene Therapeutics Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=ALLO&period=max&api_key=YOUR_API_KEY